(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 September 2018 (20.09.2018)

WIPO | PCT

(10) International Publication Number
WO 2018/170026 A3

(51) International Patent Classification:
C07K 14/705 (2006.01)

(21) International Application Number:
PCT/US2018/022270

(22) International Filing Date:
13 March 2018 (13.03.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/472,554	16 March 2017 (16.03.2017)	US
62/472,558	16 March 2017 (16.03.2017)	US
62/472,569	16 March 2017 (16.03.2017)	US
62/472,572	16 March 2017 (16.03.2017)	US
62/472,573	17 March 2017 (17.03.2017)	US
62/475,204	22 March 2017 (22.03.2017)	US
62/537,939	27 July 2017 (27.07.2017)	US
62/574,165	18 October 2017 (18.10.2017)	US
62/582,266	06 November 2017 (06.11.2017)	US

(71) Applicant: **ALPINE IMMUNE SCIENCES, INC.** [US/US]; 201 Elliott Avenue West, Suite 230, Seattle, Washington 98119 (US).

(72) Inventors: **SWANSON, Ryan**; 201 Elliott Avenue West, Suite 230, Seattle, Washington 98119 (US). **KORNACKER, Michael**; 201 Elliott Avenue West, Suite 230, Seattle, Washington 98119 (US). **MAURER, Mark F.**; 201 Elliott Avenue West, Suite 230, Seattle, Washington 98119 (US). **ARDOUREL, Dan**; 201 Elliott Avenue West, Suite 230, Seattle, Washington 98119 (US). **DEMONTE, Daniel William**; 201 Elliott Avenue West, Suite 230, Seattle, Washington 98119 (US). **KUIJPER, Joseph L.**; 201 Elliott Avenue West, Suite 230, Seattle, Washington 98119 (US).

(74) Agent: **AIKEN, Charity** et al.; 12531 High Bluff Drive, Suite 100, San Diego, California 92130-2040 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,

(54) Title: CD80 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF

FIG. 3A



(57) Abstract: Provided herein are variant CD80 polypeptides, immunomodulatory proteins comprising variant CD80 polypeptides, and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.

WO 2018/170026 A3

[Continued on next page]

KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(88) **Date of publication of the international search report:**
18 October 2018 (18.10.2018)